Genetic Variation in <i>IL-1β, IL-2, IL-6, TSPO</i> and <i>BDNF</i> and Response to Duloxetine or Placebo Treatment in Major Depressive Disorder

AIM: This study investigated polymorphisms of five inflammatory-related genes for association with duloxetine and placebo response in patients with major depression. PATIENTS & METHODS: Twenty SNPs in IL-1β, IL-2, IL-6, TSPO and BDNF were genotyped in major depressive disorder patients treated with either duloxetine (n = 215) or placebo (n = 235) for up to 8 weeks. Treatment response was measured with the Montgomery-Åsberg Depression Rating Scale. RESULTS: IL-6 variants rs2066992 and rs10242595 were nominally associated with response to duloxetine (p = 0.047 and p = 0.028, respectively). Notably, the variant rs2066992 was also associated with placebo response (p = 0.026). However, none of our results remained significant after correction for multiple testing. CONCLUSION: Our findings tentatively suggest that IL-6 variants play a role in duloxetine and placebo response, which warrants further investigation.

Genetic Variation in IL-1β, IL-2, IL-6, TSPO and BDNF and Response to Duloxetine or Placebo Treatment in Major Depressive Disorder Journal Articles